Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy

Keishi Sugimachi, Shotaro Sakimura, Shotaro Kuramitsu, Hidenari Hirata, Atsushi Niida, Tomohiro Iguchi, Hidetoshi Eguchi, Takaaki Masuda, Masaru Morita, Yasushi Toh, Yoshihiko Maehara, Yutaka Suzuki, Koshi Mimori

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

BACKGROUND: We aim to investigate the utility of serial gene mutation tracking for locally advanced CRC in those who underwent curative resection following neoadjuvant chemotherapy. METHODS: We prospectively collected 10 locally advanced CRC cases for which curative resection was performed following preoperative neoadjuvant chemotherapy. Tissues from the primary tumour, distant metastatic tumours, and blood plasma were obtained during serial treatment. Comprehensive mutation analysis of 47 cancer-associated genes was performed using a pre-designed gene panel and next-generation sequencing. RESULTS: All cases showed a partial response to neoadjuvant chemotherapy, and pathological R0 resection was accomplished. In primary tumours, non-synonymous mutations were detected at between 1 and 14 sites before chemotherapy and at between 1 and 2 sites after. Founder mutations were precisely detected in blood plasma and metastatic tumours during longitudinal treatment. CONCLUSIONS: Serial mutational analysis indicated that subclonal selection occurs during chemotherapy and that plasma can substitute for tumourous tissue in mutational analysis for drug selection and treatment decisions.

元の言語英語
ページ(範囲)419-423
ページ数5
ジャーナルBritish journal of cancer
119
発行部数4
DOI
出版物ステータス出版済み - 8 14 2018

Fingerprint

Colorectal Neoplasms
Drug Therapy
Mutation
Neoplasms
Plasma Substitutes
Neoplasm Genes
Genes
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. / Sugimachi, Keishi; Sakimura, Shotaro; Kuramitsu, Shotaro; Hirata, Hidenari; Niida, Atsushi; Iguchi, Tomohiro; Eguchi, Hidetoshi; Masuda, Takaaki; Morita, Masaru; Toh, Yasushi; Maehara, Yoshihiko; Suzuki, Yutaka; Mimori, Koshi.

:: British journal of cancer, 巻 119, 番号 4, 14.08.2018, p. 419-423.

研究成果: ジャーナルへの寄稿記事

Sugimachi, K, Sakimura, S, Kuramitsu, S, Hirata, H, Niida, A, Iguchi, T, Eguchi, H, Masuda, T, Morita, M, Toh, Y, Maehara, Y, Suzuki, Y & Mimori, K 2018, 'Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy', British journal of cancer, 巻. 119, 番号 4, pp. 419-423. https://doi.org/10.1038/s41416-018-0208-5
Sugimachi, Keishi ; Sakimura, Shotaro ; Kuramitsu, Shotaro ; Hirata, Hidenari ; Niida, Atsushi ; Iguchi, Tomohiro ; Eguchi, Hidetoshi ; Masuda, Takaaki ; Morita, Masaru ; Toh, Yasushi ; Maehara, Yoshihiko ; Suzuki, Yutaka ; Mimori, Koshi. / Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. :: British journal of cancer. 2018 ; 巻 119, 番号 4. pp. 419-423.
@article{143a32da0e2e42ec8a90e4199348e747,
title = "Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy",
abstract = "BACKGROUND: We aim to investigate the utility of serial gene mutation tracking for locally advanced CRC in those who underwent curative resection following neoadjuvant chemotherapy. METHODS: We prospectively collected 10 locally advanced CRC cases for which curative resection was performed following preoperative neoadjuvant chemotherapy. Tissues from the primary tumour, distant metastatic tumours, and blood plasma were obtained during serial treatment. Comprehensive mutation analysis of 47 cancer-associated genes was performed using a pre-designed gene panel and next-generation sequencing. RESULTS: All cases showed a partial response to neoadjuvant chemotherapy, and pathological R0 resection was accomplished. In primary tumours, non-synonymous mutations were detected at between 1 and 14 sites before chemotherapy and at between 1 and 2 sites after. Founder mutations were precisely detected in blood plasma and metastatic tumours during longitudinal treatment. CONCLUSIONS: Serial mutational analysis indicated that subclonal selection occurs during chemotherapy and that plasma can substitute for tumourous tissue in mutational analysis for drug selection and treatment decisions.",
author = "Keishi Sugimachi and Shotaro Sakimura and Shotaro Kuramitsu and Hidenari Hirata and Atsushi Niida and Tomohiro Iguchi and Hidetoshi Eguchi and Takaaki Masuda and Masaru Morita and Yasushi Toh and Yoshihiko Maehara and Yutaka Suzuki and Koshi Mimori",
year = "2018",
month = "8",
day = "14",
doi = "10.1038/s41416-018-0208-5",
language = "English",
volume = "119",
pages = "419--423",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy

AU - Sugimachi, Keishi

AU - Sakimura, Shotaro

AU - Kuramitsu, Shotaro

AU - Hirata, Hidenari

AU - Niida, Atsushi

AU - Iguchi, Tomohiro

AU - Eguchi, Hidetoshi

AU - Masuda, Takaaki

AU - Morita, Masaru

AU - Toh, Yasushi

AU - Maehara, Yoshihiko

AU - Suzuki, Yutaka

AU - Mimori, Koshi

PY - 2018/8/14

Y1 - 2018/8/14

N2 - BACKGROUND: We aim to investigate the utility of serial gene mutation tracking for locally advanced CRC in those who underwent curative resection following neoadjuvant chemotherapy. METHODS: We prospectively collected 10 locally advanced CRC cases for which curative resection was performed following preoperative neoadjuvant chemotherapy. Tissues from the primary tumour, distant metastatic tumours, and blood plasma were obtained during serial treatment. Comprehensive mutation analysis of 47 cancer-associated genes was performed using a pre-designed gene panel and next-generation sequencing. RESULTS: All cases showed a partial response to neoadjuvant chemotherapy, and pathological R0 resection was accomplished. In primary tumours, non-synonymous mutations were detected at between 1 and 14 sites before chemotherapy and at between 1 and 2 sites after. Founder mutations were precisely detected in blood plasma and metastatic tumours during longitudinal treatment. CONCLUSIONS: Serial mutational analysis indicated that subclonal selection occurs during chemotherapy and that plasma can substitute for tumourous tissue in mutational analysis for drug selection and treatment decisions.

AB - BACKGROUND: We aim to investigate the utility of serial gene mutation tracking for locally advanced CRC in those who underwent curative resection following neoadjuvant chemotherapy. METHODS: We prospectively collected 10 locally advanced CRC cases for which curative resection was performed following preoperative neoadjuvant chemotherapy. Tissues from the primary tumour, distant metastatic tumours, and blood plasma were obtained during serial treatment. Comprehensive mutation analysis of 47 cancer-associated genes was performed using a pre-designed gene panel and next-generation sequencing. RESULTS: All cases showed a partial response to neoadjuvant chemotherapy, and pathological R0 resection was accomplished. In primary tumours, non-synonymous mutations were detected at between 1 and 14 sites before chemotherapy and at between 1 and 2 sites after. Founder mutations were precisely detected in blood plasma and metastatic tumours during longitudinal treatment. CONCLUSIONS: Serial mutational analysis indicated that subclonal selection occurs during chemotherapy and that plasma can substitute for tumourous tissue in mutational analysis for drug selection and treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=85052282409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052282409&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0208-5

DO - 10.1038/s41416-018-0208-5

M3 - Article

AN - SCOPUS:85052282409

VL - 119

SP - 419

EP - 423

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -